Analysts expect that Neuronetics Inc (NASDAQ:STIM) will report earnings of ($0.41) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Neuronetics’ earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.40). Neuronetics reported earnings per share of ($0.29) in the same quarter last year, which indicates a negative year over year growth rate of 41.4%. The company is expected to announce its next earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Neuronetics will report full-year earnings of ($1.61) per share for the current year, with EPS estimates ranging from ($1.62) to ($1.59). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.61) per share, with EPS estimates ranging from ($1.73) to ($1.48). Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Neuronetics.
Neuronetics (NASDAQ:STIM) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. The company had revenue of $16.57 million for the quarter, compared to analysts’ expectations of $15.80 million. Neuronetics had a negative net margin of 43.85% and a negative return on equity of 37.75%.
Shares of NASDAQ:STIM traded up $0.10 during midday trading on Monday, reaching $10.10. 38,736 shares of the company were exchanged, compared to its average volume of 107,452. Neuronetics has a fifty-two week low of $8.90 and a fifty-two week high of $39.39. The company has a quick ratio of 5.95, a current ratio of 6.10 and a debt-to-equity ratio of 0.51. The stock has a fifty day simple moving average of $11.69 and a two-hundred day simple moving average of $14.28. The firm has a market cap of $186.70 million, a PE ratio of -3.75 and a beta of 0.97.
In related news, insider Daniel Guthrie sold 3,685 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $14.53, for a total transaction of $53,543.05. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 12.00% of the company’s stock.
Large investors have recently modified their holdings of the stock. Advisor Group Inc. acquired a new stake in Neuronetics in the 4th quarter valued at $27,000. BNP Paribas Arbitrage SA acquired a new stake in Neuronetics in the 1st quarter valued at $41,000. Bank of America Corp DE increased its stake in Neuronetics by 967.7% in the 4th quarter. Bank of America Corp DE now owns 5,787 shares of the company’s stock valued at $111,000 after buying an additional 5,245 shares during the last quarter. Rhumbline Advisers acquired a new stake in Neuronetics in the 1st quarter valued at $204,000. Finally, Millennium Management LLC acquired a new stake in Neuronetics in the 4th quarter valued at $303,000. Institutional investors and hedge funds own 78.81% of the company’s stock.
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Featured Story: Example of operating income, EBIT and EBITDA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.